8-K: Teladoc CFO Resigns, Reaffirms 2025 Outlook Amid Q3 Prelim

Teladoc Health announced its CFO, Mala Murthy, will resign effective November 21, 2025, while reaffirming its full-year 2025 consolidated financial outlook and providing preliminary third-quarter results.

Summary

• Mala Murthy, Chief Financial Officer, will resign effective November 21, 2025, to pursue an opportunity outside the healthcare industry.
• The company has initiated a search for a new CFO and will implement an interim leadership structure with key finance leaders reporting to the CEO.
• Preliminary unaudited consolidated revenue for the third quarter ended September 30, 2025, was $626.4 million.
• Preliminary unaudited consolidated adjusted EBITDA for the third quarter ended September 30, 2025, was $69.9 million.
• Preliminary unaudited net loss for the third quarter ended September 30, 2025, was $49.5 million, compared to a net loss of $33.3 million in the third quarter of 2024.
• The company reaffirmed its full-year 2025 consolidated revenue and adjusted EBITDA outlook, consistent with guidance issued on July 29, 2025.
• Segment-level results for the year ending December 31, 2025, are expected to be discussed further on the company's conference call on October 29, 2025.

Sentiment

Score: 5

Explanation: The reaffirmation of the full-year outlook provides some stability, but the preliminary Q3 results show a decline in adjusted EBITDA and an increased net loss year-over-year. The CFO's resignation, especially to leave the industry, adds an element of uncertainty, balancing out the reaffirmed guidance.

Positives

• The company reaffirmed its full-year 2025 consolidated revenue and adjusted EBITDA outlook, indicating stability in management's expectations.
• CFO Mala Murthy's departure is not due to any disagreement with the company's operations, policies, or practices.

Negatives

• Preliminary third quarter 2025 net loss increased to $49.5 million from $33.3 million in the third quarter of 2024.
• Preliminary third quarter 2025 consolidated adjusted EBITDA decreased to $69.9 million from $83.3 million in the third quarter of 2024.
• The departure of a key executive, the Chief Financial Officer, creates uncertainty during a transition period.
• The CFO is leaving the healthcare industry, which might suggest a lack of long-term confidence in the sector or the company's specific trajectory.

Risks

• Changes in laws and regulations applicable to the business model.
• Changes in market conditions and receptivity to services and offerings, including the ability to effectively compete.
• Results of litigation or regulatory actions.
• Loss of one or more key clients or a significant number of members or BetterHelp paying users.
• Changes in valuations or useful lives of assets.
• Changes to the ability to recruit and retain qualified providers into the network.
• Impact of and risk related to impairment losses with respect to goodwill or other assets.
• The success of the operational review to achieve a more balanced approach to growth and margin.
• Imposed and threatened tariffs by the United States and its trading partners, and any resulting disruptions or inefficiencies in the supply chain.

Future Outlook

The company continues to expect its consolidated financial results for the year ending December 31, 2025, to be consistent with the outlook range disclosed in its second-quarter earnings release on July 29, 2025. Segment-level results for the full year will be discussed further on the upcoming October 29, 2025, conference call.

Management Comments

• "On behalf of our board of directors, leadership team and employees, I would like to thank Mala Murthy for her six years of service to our company. As CFO, Mala made significant contributions to the company, building financial strength and advancing strategic priorities to support our market leadership position. I want to personally thank Mala for her partnership and wish her well in her next role." Chuck Divita, CEO.
• "It has been a privilege to serve as Teladoc Healths Chief Financial Officer during a pivotal time in virtual care. I’m deeply grateful for the opportunity to have worked with such an exceptional, committed team." Mala Murthy.

Industry Context

Teladoc Health operates in the rapidly evolving virtual care industry, which continues to see shifts in patient adoption, regulatory frameworks, and competitive landscapes. The departure of a key finance executive and the reaffirmation of guidance suggest the company is navigating these dynamics while maintaining its strategic priorities, though preliminary Q3 results indicate ongoing challenges in profitability compared to the prior year.

Management Changes

Stakeholder Impact

• Shareholders: Potential uncertainty due to CFO departure and preliminary Q3 results showing increased net loss and decreased adjusted EBITDA year-over-year, balanced by reaffirmed full-year guidance.
• Employees: Potential impact on the finance team due to leadership transition and interim structure.
• Customers/Providers: No direct impact mentioned, but stability in leadership and financial performance can indirectly affect service quality and network retention.

Next Steps

• Complete the financial closing process and prepare full financial statements for the third quarter of 2025.
• Host a conference call on October 29, 2025, to discuss third quarter 2025 financial results and provide segment-level details for the full year 2025 outlook.
• Initiate and complete a search process to identify a new Chief Financial Officer.
• Implement an interim leadership structure for the finance function until a new CFO is appointed.

Key Dates

Recommendation

The filing presents a mixed bag. The CFO's resignation, particularly to leave the industry, introduces an element of uncertainty and could be perceived negatively by the market. Furthermore, the preliminary Q3 results show a year-over-year decline in adjusted EBITDA and an increased net loss, which are concerning. However, the company has reaffirmed its full-year 2025 consolidated outlook, suggesting these preliminary Q3 results are within their expected range. This reaffirmation provides some stability. Given the executive transition and the preliminary financial performance, a 'hold' recommendation is appropriate as investors await the full Q3 earnings details and further clarity on the CFO search and strategic direction.

Keywords

Teladoc Health, TDOC, CFO resignation, financial results, Q3 2025, earnings outlook, virtual care, telehealth, adjusted EBITDA, revenue, management change